Wealth manager recommends Novo Nordisk as a strong short-term investment due to potential drug pricing

From Yahoo Finance: 2025-04-22 14:07:00

Rebecca Walser of Walser Wealth Management recommends Novo Nordisk (NVO) as a strong short-term investment due to potential Congressional approval for extended drug pricing. NVO is currently 57% below its all-time high and has a 2.4% dividend yield.

Walser also sees semiconductor equipment maker Lam Research (LRCX) as a good near-term pick, citing its 40% discount from all-time highs and expected positive announcements or strong earnings. LRCX is set to reveal quarterly earnings soon.

While NVO shows promise, Walser believes AI stocks offer greater returns. An AI stock has seen growth since the start of 2025, outperforming popular AI stocks. For a promising AI stock trading at less than 5 times earnings, check out a report on the cheapest AI stock.

Read more: Novo Nordisk (NVO) Is a Good Short-Term Pick, Wealth Manager Says